No Data
Novo Nordisk's Ozempic Gets EU Regulator Endorsement to Reduce Kidney Risks
CFRA Initiates Novo-Nordisk A/S(NVO.US) With Hold Rating, Announces Target Price $122
Unusual Options Activity: YMM, SHAK and Others Attract Market Bets, YMM V/OI Ratio Reaches 100.0
Latest research confirms: Novo-Nordisk A/S Ozempic is associated with a rare risk of vision loss.
① A latest study confirms that Ozempic, a star drug from the Danish pharmaceutical giant Novo-Nordisk A/S, is associated with an increased risk of a rare eye disease that leads to vision loss; ② According to an analysis by Nordic researchers of years of patient records from Denmark and Norway, diabetic patients using Ozempic are more than twice as likely to develop NAION compared to patients using another diabetes medication.
Market Whales and Their Recent Bets on NVO Options
Novo Nordisk Shares Are Trading Lower Following a Report Suggesting a Study Linked Ozempic to an Increased Risk of a Rare Form of Vision Loss.
No Data
